These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19396953)

  • 41. Navigating the maze of hepatitis B treatments.
    Lok AS
    Gastroenterology; 2007 Apr; 132(4):1586-94. PubMed ID: 17408643
    [No Abstract]   [Full Text] [Related]  

  • 42. Outcomes of hepatitis B surface antigenaemia in patients with incident end-stage renal disease.
    Kim AJ; Lee JH; Ko KP; Jung ES; Choi BH; Ro H; Jung JY; Lee HH; Chung W; Chang JH
    Nephrology (Carlton); 2016 Nov; 21(11):968-974. PubMed ID: 26617162
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [New advances in the treatment of chronic hepatitis B: position of entecavir].
    Olaso V
    Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
    [No Abstract]   [Full Text] [Related]  

  • 44. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 45. Hepatitis B reactivation and timing for prophylaxis.
    Tuna N; Karabay O
    World J Gastroenterol; 2015 Feb; 21(7):2263-4. PubMed ID: 25717269
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment eligibility in hepatitis B: a call for better linkage to optimal care.
    Huang DQ; Nguyen MH
    Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):160. PubMed ID: 33581753
    [No Abstract]   [Full Text] [Related]  

  • 47. Editorial overview: Antiviral strategies: Virological and immunological basis for HBV cure.
    Urban S; Bertoletti A
    Curr Opin Virol; 2018 Jun; 30():iv-vi. PubMed ID: 29866361
    [No Abstract]   [Full Text] [Related]  

  • 48. Screening for Hepatitis B: Serology Markers Interpretation.
    Cadet MJ
    Workplace Health Saf; 2018 Oct; 66(10):512. PubMed ID: 30136615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Hepatitis B virus infection among medical personnel in the Perm district].
    Volegova GM; Khromova GV; Myshkina OK; Eĭkhner EE; Medvedev VD; Mal'tseva NI
    Sov Med; 1991; (10):63-5. PubMed ID: 1839338
    [No Abstract]   [Full Text] [Related]  

  • 50. Time-resolved fluoroimmunoassay for hepatitis B virus PreS1 antigen detection.
    Joob B; Wiwanitkit V
    J Immunoassay Immunochem; 2012; 33(3):337. PubMed ID: 22738656
    [No Abstract]   [Full Text] [Related]  

  • 51. Preventing infection-associated cancer: from bench to hillside.
    Goedert JJ
    J Natl Cancer Inst; 2005 Feb; 97(4):245-6. PubMed ID: 15713953
    [No Abstract]   [Full Text] [Related]  

  • 52. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
    Liu CY; Chandrasekar PH; Masood A; Schiffer CA
    J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in the diagnosis and treatment of hepatitis B.
    Alazawi W; Foster GR
    Curr Opin Infect Dis; 2008 Oct; 21(5):508-15. PubMed ID: 18725801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Advance in clinical studies of the kinetics of hepatitis B virus].
    Tang YT; Cao Q; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
    [No Abstract]   [Full Text] [Related]  

  • 55. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa.
    Béguelin C; Fall F; Seydi M; Wandeler G
    Expert Rev Gastroenterol Hepatol; 2018 Jun; 12(6):537-546. PubMed ID: 29737218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatitis B surface antigen seroreversion in a T-cell lymphoma patient.
    Chen HW; Lin SA; Lin HC; Kao WY
    J BUON; 2011; 16(2):374-6. PubMed ID: 21766517
    [No Abstract]   [Full Text] [Related]  

  • 57. Introduction to 'Hepatitis B virus heterogeneity--a means to personalized care'.
    Bonino F;
    Antivir Ther; 2010; 15 Suppl 3():1-2. PubMed ID: 21041898
    [No Abstract]   [Full Text] [Related]  

  • 58. Antiviral therapy in hepatitis B infection.
    Thomas HC; Scully LJ
    Br Med Bull; 1985 Oct; 41(4):374-80. PubMed ID: 3902143
    [No Abstract]   [Full Text] [Related]  

  • 59. Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress.
    Guo P
    Scand J Immunol; 2013 Sep; 78(3):230-7. PubMed ID: 23790137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Chou R; Dana T; Bougatsos C; Blazina I; Khangura J; Zakher B
    Ann Intern Med; 2014 Jul; 161(1):31-45. PubMed ID: 24861032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.